STOCK TITAN

Axsome Therapeutics Inc - AXSM STOCK NEWS

Welcome to our dedicated news page for Axsome Therapeutics (Ticker: AXSM), a resource for investors and traders seeking the latest updates and insights on Axsome Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Axsome Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Axsome Therapeutics's position in the market.

Rhea-AI Summary
Axsome Therapeutics showcases its innovative neuroscience portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting, featuring data on AXS-05 in Alzheimer's disease agitation, AXS-07 in migraine, and solriamfetol's cognitive and wake promoting effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
none
-
Rhea-AI Summary
Axsome Therapeutics, Inc. (NASDAQ: AXSM) will report its financial results for Q1 2024 on May 6, 2024. The management team will discuss the results and provide a business update in a conference call at 8:00 a.m. Eastern Time. Participants can join via phone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
conferences earnings
-
Rhea-AI Summary
Axsome Therapeutics initiates Phase 3 trial of solriamfetol for binge eating disorder, aiming to assess efficacy and safety in adults.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.52%
Tags
Rhea-AI Summary
Axsome Therapeutics, Inc. (NASDAQ: AXSM) released topline results from the CRESCENDO survey, revealing high rates of persistent symptoms in narcolepsy type 1 patients despite treatment. The survey, conducted in partnership with Narcolepsy Network, highlighted significant patient burden, with 77% experiencing cataplexy attacks, 64% facing excessive daytime sleepiness, and 74% exhibiting cognitive impairment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
none
-
Rhea-AI Summary
Axsome Therapeutics, Inc. announces positive Phase 3 trial results for AXS-12 in narcolepsy treatment, achieving primary endpoint with significant reductions in cataplexy attacks, EDS severity, and cognitive function compared to placebo. The company plans to present detailed trial results at upcoming scientific meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
-
Rhea-AI Summary
Axsome Therapeutics, Inc. (NASDAQ: AXSM) initiates Phase 3 trial for solriamfetol in major depressive disorder, dosing the first patient. The PARADIGM trial aims to evaluate efficacy and safety in 300 patients over 6 weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.97%
Tags
Rhea-AI Summary
Axsome Therapeutics, Inc. CEO to participate in a fireside chat at Leerink Partners Global Biopharma Conference. The event will be held on March 13, 2024, at 9:20 a.m. Eastern Time in Miami Beach, Florida. Investors can watch the live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
conferences
-
Rhea-AI Summary
Axsome Therapeutics, Inc. (NASDAQ: AXSM) announced that its CEO will participate in a fireside chat at a healthcare conference. The event will be webcasted on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
conferences
-
Rhea-AI Summary
Axsome Therapeutics, Inc. reports impressive financial results for 4Q and full year 2023 with net product revenue of $71.5 million and $204.9 million, respectively, showing significant growth. The company highlights successful commercial execution, pipeline advancement, and expansion. Key milestones include NDA submissions for AXS-14 in fibromyalgia and AXS-07 in migraine, with topline results of Phase 3 trials expected in 2024. Financially, total revenue for 2023 was $270.6 million, with total net product revenue growth of 309% year-over-year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.57%
Tags
Rhea-AI Summary
Axsome Therapeutics, Inc. (NASDAQ: AXSM) will report its financial results for the fourth quarter and full year of 2023 on Tuesday, Feb. 20, 2024, before the opening of the U.S. financial markets. The management team will host a conference call at 8:00 a.m. Eastern Time on Feb. 20, 2024, to discuss these results and provide a business update. Participants can join the live conference call by dialing (877) 405-1239 (toll-free domestic) or accessing the webcast on the Company’s website at www.axsome.com. A recording of the conference call will be available on the website for approximately 30 days following the live event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
conferences earnings
Axsome Therapeutics Inc

Nasdaq:AXSM

AXSM Rankings

AXSM Stock Data

3.26B
34.88M
17.12%
83.32%
16.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About AXSM

axsome therapeutics is a biopharmaceutical company developing novel therapies for the treatment of cns disorders. axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. the company is based in new york city.